SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-24-000102
Filing Date
2024-06-05
Accepted
2024-06-05 16:15:27
Documents
16
Period of Report
2024-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K xers-20240605.htm   iXBRL 8-K 49106
2 EX-10.1 ex101xeris-amendmentno1t.htm EX-10.1 3076
7 ex101xeris-amendmentno1t001.jpg GRAPHIC 202785
  Complete submission text file 0001867096-24-000102.txt   493089

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20240605.xsd EX-101.SCH 2155
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20240605_def.xml EX-101.DEF 15406
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20240605_lab.xml EX-101.LAB 27075
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20240605_pre.xml EX-101.PRE 16120
19 EXTRACTED XBRL INSTANCE DOCUMENT xers-20240605_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 241022186
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)